Lucid Diagnostics Net Income
| LUCD Stock | USD 1.21 0.00 0.00% |
As of the 2nd of February, Lucid Diagnostics secures the Standard Deviation of 3.35, mean deviation of 2.42, and Risk Adjusted Performance of 0.001. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lucid Diagnostics, as well as the relationship between them. Please verify Lucid Diagnostics variance, as well as the relationship between the maximum drawdown and skewness to decide if Lucid Diagnostics is priced some-what accurately, providing market reflects its recent price of 1.21 per share. Given that Lucid Diagnostics is a hitting penny stock territory we strongly suggest to closely look at its jensen alpha.
Lucid Diagnostics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 42.5743 | Revenue | Earnings Share (0.77) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -50.6 M | -48 M | |
| Net Loss | -41 M | -43 M | |
| Net Loss | -41 M | -43 M | |
| Net Loss | (1.04) | (1.09) |
Lucid | Net Income | Build AI portfolio with Lucid Stock |
Analyzing Lucid Diagnostics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Lucid Diagnostics's current valuation and future prospects.
Latest Lucid Diagnostics' Net Income Growth Pattern
Below is the plot of the Net Income of Lucid Diagnostics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Lucid Diagnostics financial statement analysis. It represents the amount of money remaining after all of Lucid Diagnostics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Lucid Diagnostics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lucid Diagnostics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (45.53 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Lucid Net Income Regression Statistics
| Arithmetic Mean | (17,016,416) | |
| Coefficient Of Variation | (127.21) | |
| Mean Deviation | 19,334,884 | |
| Median | (1,126,000) | |
| Standard Deviation | 21,646,803 | |
| Sample Variance | 468.6T | |
| Range | 55M | |
| R-Value | (0.83) | |
| Mean Square Error | 153T | |
| R-Squared | 0.69 | |
| Significance | 0.000033 | |
| Slope | (3,570,827) | |
| Total Sum of Squares | 7497.3T |
Lucid Net Income History
Other Fundumenentals of Lucid Diagnostics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Lucid Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Lucid Diagnostics is extremely important. It helps to project a fair market value of Lucid Stock properly, considering its historical fundamentals such as Net Income. Since Lucid Diagnostics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lucid Diagnostics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lucid Diagnostics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Health Care Equipment & Supplies sector continue expanding? Could Lucid diversify its offerings? Factors like these will boost the valuation of Lucid Diagnostics. Expected growth trajectory for Lucid significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lucid Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.77) | Revenue Per Share | Quarterly Revenue Growth 0.033 | Return On Assets | Return On Equity |
Understanding Lucid Diagnostics requires distinguishing between market price and book value, where the latter reflects Lucid's accounting equity. The concept of intrinsic value—what Lucid Diagnostics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lucid Diagnostics' price substantially above or below its fundamental value.
Understanding that Lucid Diagnostics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lucid Diagnostics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lucid Diagnostics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Lucid Diagnostics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Lucid Diagnostics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Lucid Diagnostics.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Lucid Diagnostics on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Lucid Diagnostics or generate 0.0% return on investment in Lucid Diagnostics over 90 days. Lucid Diagnostics is related to or competes with Rapid Micro, Apyx Medical, Avita Medical, Opus Genetics, Sharps Technology, Anteris Technologies, and Seer. Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company More
Lucid Diagnostics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Lucid Diagnostics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Lucid Diagnostics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 18.0 | |||
| Value At Risk | (4.92) | |||
| Potential Upside | 4.76 |
Lucid Diagnostics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lucid Diagnostics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Lucid Diagnostics' standard deviation. In reality, there are many statistical measures that can use Lucid Diagnostics historical prices to predict the future Lucid Diagnostics' volatility.| Risk Adjusted Performance | 0.001 | |||
| Jensen Alpha | (0.05) | |||
| Total Risk Alpha | (0.20) | |||
| Treynor Ratio | (0.19) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lucid Diagnostics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Lucid Diagnostics February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.001 | |||
| Market Risk Adjusted Performance | (0.18) | |||
| Mean Deviation | 2.42 | |||
| Coefficient Of Variation | (10,531) | |||
| Standard Deviation | 3.35 | |||
| Variance | 11.25 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.05) | |||
| Total Risk Alpha | (0.20) | |||
| Treynor Ratio | (0.19) | |||
| Maximum Drawdown | 18.0 | |||
| Value At Risk | (4.92) | |||
| Potential Upside | 4.76 | |||
| Skewness | 0.7057 | |||
| Kurtosis | 2.79 |
Lucid Diagnostics Backtested Returns
At this point, Lucid Diagnostics is very risky. Lucid Diagnostics has Sharpe Ratio of 0.0565, which conveys that the firm had a 0.0565 % return per unit of risk over the last 3 months. We have found twenty-two technical indicators for Lucid Diagnostics, which you can use to evaluate the volatility of the firm. Please verify Lucid Diagnostics' Standard Deviation of 3.35, risk adjusted performance of 0.001, and Mean Deviation of 2.42 to check out if the risk estimate we provide is consistent with the expected return of 0.18%. Lucid Diagnostics has a performance score of 4 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.22, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Lucid Diagnostics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Lucid Diagnostics is expected to be smaller as well. Lucid Diagnostics right now secures a risk of 3.25%. Please verify Lucid Diagnostics information ratio, skewness, market facilitation index, as well as the relationship between the treynor ratio and rate of daily change , to decide if Lucid Diagnostics will be following its current price movements.
Auto-correlation | -0.13 |
Insignificant reverse predictability
Lucid Diagnostics has insignificant reverse predictability. Overlapping area represents the amount of predictability between Lucid Diagnostics time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Lucid Diagnostics price movement. The serial correlation of -0.13 indicates that less than 13.0% of current Lucid Diagnostics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.13 | |
| Spearman Rank Test | -0.08 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Lucid Diagnostics reported net income of (45.53 Million). This is 113.34% lower than that of the Health Care Equipment & Supplies sector and 119.12% lower than that of the Health Care industry. The net income for all United States stocks is 107.97% higher than that of the company.
Lucid Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lucid Diagnostics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lucid Diagnostics could also be used in its relative valuation, which is a method of valuing Lucid Diagnostics by comparing valuation metrics of similar companies.Lucid Diagnostics is currently under evaluation in net income category among its peers.
Lucid Diagnostics Institutional Holders
Institutional Holdings refers to the ownership stake in Lucid Diagnostics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Lucid Diagnostics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lucid Diagnostics' value.| Shares | Goldman Sachs Group Inc | 2025-06-30 | 308.7 K | Renaissance Technologies Corp | 2025-06-30 | 243.3 K | Nuveen, Llc | 2025-06-30 | 243.3 K | Wells Fargo & Co | 2025-06-30 | 226.9 K | Xml Financial, Llc | 2025-06-30 | 178.8 K | Charles Schwab Investment Management Inc | 2025-06-30 | 174.9 K | Bank Of New York Mellon Corp | 2025-06-30 | 156.9 K | Barclays Plc | 2025-06-30 | 120 K | Squarepoint Ops Llc | 2025-06-30 | 112.2 K | Vanguard Group Inc | 2025-06-30 | 4.1 M | Blackrock Inc | 2025-06-30 | 3.6 M |
Lucid Fundamentals
| Return On Equity | -3.31 | ||||
| Return On Asset | -0.79 | ||||
| Operating Margin | (9.71) % | ||||
| Current Valuation | 180.73 M | ||||
| Shares Outstanding | 131.1 M | ||||
| Shares Owned By Insiders | 35.29 % | ||||
| Shares Owned By Institutions | 29.00 % | ||||
| Number Of Shares Shorted | 3.8 M | ||||
| Price To Book | 2.16 X | ||||
| Price To Sales | 35.46 X | ||||
| Revenue | 4.35 M | ||||
| Gross Profit | (2.56 M) | ||||
| EBITDA | (44.34 M) | ||||
| Net Income | (45.53 M) | ||||
| Cash And Equivalents | 34.46 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 21.25 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.55 X | ||||
| Book Value Per Share | (0.23) X | ||||
| Cash Flow From Operations | (44.14 M) | ||||
| Short Ratio | 6.46 X | ||||
| Earnings Per Share | (0.77) X | ||||
| Target Price | 3.79 | ||||
| Number Of Employees | 72 | ||||
| Beta | 1.22 | ||||
| Market Capitalization | 156.01 M | ||||
| Total Asset | 30.71 M | ||||
| Retained Earnings | (203.77 M) | ||||
| Working Capital | 1.62 M | ||||
| Net Asset | 30.71 M |
About Lucid Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lucid Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lucid Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lucid Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:Check out For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Will Health Care Equipment & Supplies sector continue expanding? Could Lucid diversify its offerings? Factors like these will boost the valuation of Lucid Diagnostics. Expected growth trajectory for Lucid significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lucid Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.77) | Revenue Per Share | Quarterly Revenue Growth 0.033 | Return On Assets | Return On Equity |
Understanding Lucid Diagnostics requires distinguishing between market price and book value, where the latter reflects Lucid's accounting equity. The concept of intrinsic value—what Lucid Diagnostics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lucid Diagnostics' price substantially above or below its fundamental value.
Understanding that Lucid Diagnostics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lucid Diagnostics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lucid Diagnostics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.